Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-10-30
2001-04-03
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S338000, C514S388000
Reexamination Certificate
active
06211200
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to G-CSFR metal complexed ligands, methods for making and identifying them and their use as agonist of G-CSFR.
BACKGROUND OF THE INVENTION
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein secreted by macrophages, fibroblasts, and endothelial cells originally identified by its ability to stimulate the survival, proliferation, and differentiation in vitro of predominantly neutrophilic granulocytes from bone marrow progenitors (Nicola, N. A.,
Annu. Rev. Biochem. (
1989) 58:45). The capacity of G-CSF to regulate in vivo granulopoiesis is supported by animal and clinical studies, which demonstrated a reversible rise in circulating neutrophil levels in response to administered recombinant G-CSF (Gabrilove, J. L. et al.,
N. Engl. J. Med.
(1988) 318:1414). G-CSF has pleiotropic effects on mature neutrophils, enhancing their survival and stimulating functional activation, including induction of neutrophil alkaline phosphatase (Sato. N. et al.,
J. Cell. Physiol.
(1988) 37:272) and high affinity IgA F
c
receptors (Weisbart, R. H., et al.,
Nature
(
Lond.
) (1988) 332:647), priming for respiratory burst (Nathan, C. F.
Blood
(1989) 73:301) and increased chemotaxis (Wang, J. M.,
Blood
(1988) 72:1456). G-CSF effects have also been observed on hematopoietic cells that are not committed to the granulocyte lineage, for example, stimulation of the proliferation on monocytic differentiation in vitro of some myeloid leukemic cells (Geissler, K.,
J. Immunol.
(1989) 143:140) and the proliferation in vitro of some multipotential hematopoietic precursors (Ferrero, D.,
Blood
(1989) 73:402).
G-CSF activates intracellular processes by binding to the granulocycte colony stimulating factor receptor (G-CSF receptor) (Demetri, G. D. and Griffin J. D., Blood 1991, 78, 2791; Avalos, B. R. Blood, 1996, 88, 761). The G-CSF receptor is single transmembrane cytokine cell surface receptor composed of three domains: an extracellular ligand binding domain, a transmembrane domain, and an intracellular signal transduction domain. It is now clear that signal transduction by cytokines is accomplished by ligand-mediated receptor dimerization (Ullrich, A. and Schlessinger, J., “Signal transduction by receptors with tyrosine kinase activity”, Cell, 61″ 203-212 (1990); Kishimoto, T., Taga, T., and Akira, S., “Cytokine signal transduction”,
Cell,
76: 253-262 (1994); Heldin, C. H., “Dimerization of cell surface receptors in signal transduction”,
Cell,
80: 213-223 (1995); Lemmon, M. A. and Schlessinger, J., “Regulation of signal transduction and signal diversity by receptor oligomerization”,
Trends Biol. Sci.,
19: 459-463 (1994)). G-CSF binds to two receptor subunits resulting in homodimerization, an event that promotes activation of cytoplasmic tyrosine kinases that associate with the intracellular domain of the recptors. This tyrosine kinase activity then initiates a cascade of intracellular processes.
Administration of recombinant G-CSF to patients suffering from neutropenia due to various causes indicated that G-CSF is beneficial as an adjuvant in chemotherapy and in bone marrow transplantation (Morstyn, G., et al.,
Trends Pharmacol. Sci.
10, (1989) 154-159). G-CSF activity is also associated with mobilization of hematopoietic stem cells from the marrow to the peripheral blood. (Haylock et al.,
Blood
89:2233-2258, 1997).
Despite the success of recombinant G-CSF in producing an agonist response at the G-CSF receptor, it is not considered an ideal pharmaceutical treatment. Lack of oral bioavailability and a limited serum half-life limit the desirability and efficacy of recombinant G-CSF as a pharmaceutical agent. Consequently, the need exists to provide improved ligands which have agonist properties towards the G-CSF receptor.
The human G-CSF receptor was first sequenced in 1990 (Fukunaga, R., Seto, Y., Mizushima, S., and Nagata, S. Three different mRNAs encoding human granulocyte colony-stimulating factor receptor
Proc. Natl. Acad. Sci. U.S.A.
87(22):8702-8706, 1990) and had already been characterized by radioligand studies on purified human blood neutrophils by 1986 (Nicola N A; Vadas M A; Lopez A F, J-Cell-Physiol. 1986, 128 501-9). Notwithstanding the fact that assay tools have been available for over a decade, only one application (PCT/US97/08864) describes small organic molecules which exhibit G-CSF mimetic activity. This application does not mention zinc chelated small organic molecules.
As disclosed herein it has unexpectedly been discovered that certain selected zinc chelated receptor ligands have agonist properties towards the G-CSF receptor.
This discovery, that zinc chelated small organic molecules exhibit agonist activity towards the G-CSF receptor is particularly surprising in view of the finding that the natural ligand for the G-CSF receptor (i.e. G-CSF or recombinant G-CSF) does not utilize zinc chelation during activation. This finding is exemplified and further discussed in the examples below.
SUMMARY OF THE INVENTION
Accordingly, one aspect of the present invention is a method for agonizing the G-CSF receptor comprising contacting the receptor with a zinc chelated G-CSF receptor ligand.
Another aspect of the invention is a method for identifying agonists of the G-CSF receptor.
A third aspect of the invention relates to zinc chelated G-CSF receptor ligands.
A fourth aspect of the invention relates to an isolated G-CSF receptor binding moiety of a zinc chelated G-CSF receptor ligand.
A fifth aspect of the invention is a method for making zinc chelated G-CSF receptor ligands.
REFERENCES:
patent: 5693515 (1997-12-01), Clark et al.
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5869451 (1999-02-01), Dower et al.
patent: 5981551 (1999-11-01), Luengo et al.
patent: WO99/11262 (1999-03-01), None
Botros et al., “Immobilized metal ion affinity partitioning of cells in aqueous two-phase systems:erythrocytes as a model”,Biochimica et Biophysica Acta,1074, pp. 69-73 (1991).
Arai et al., “Bleomycin Model Complex Bearing A Carbamoyl Derived Sustituent Capable of Coordination to the Chelated Metal Ion As A Sixth Ligand”,Bioorganic&Medicinal Chemistry Letters,7(1), pp. 15-18 (1997).
Rao et al., Technetium(V) and Rhenium(V) Complexes of 2,3-Bis(mercaptoacetamido)propanoate. Chelate Ring Stereochemistry and Influence on Chemical and Biologial Properties,J. Am. Chem. Soc.,112, pp. 5798-5804 (1990).
Katz et al., “Design of potent selective zinc-mediated serine protease inhibitors”,Letters to Nature,391, pp. 608-613 (1998).
Bergeron et al., “Synthesis and Biological Evaluation of Naphthyldesferrithiocin Iron Chelators”,J. Med. Chem.,39, pp. 1575-1581 (1996).
Chi et al., “Homodimeric and Heterodimeric Bis(amino thiol) Oxometal Complexes with Rhenium(V) and Technetium(V). Control of Heterodimeric Complex Formation and an Approach to Metal Complexes that Mimic Steriod Hormones”,J. Med. Chem.,37, pp. 928-937 (1994).
Wrighton et al., “Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin”,Science,273, pp. 458-463 (1996).
Cwirla et al., “Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine”,Science,276, pp. 1696-1699 (1997).
Linvah et al., “Functional Mimicry of a Protein Hormone by a Peptide Agonist:The EPO Receptor Complex at 2.8A”,Science,273, pp. 464-471 (1996).
Klekota et al., “Generation of Novel DNA-Binding Compounds by Selection and Amplification from Self-Assembled Combinatorial Libraries”,Tetrahedron Letters,38(50), pp. 8639-8642 (1997).
Chi et al., “Selective F ormation of Heterodimeric Bis-Bidentate Aminothiol-Oxometal Complexes of Rhenium(V)”,J. Am. Chem. Soc.,115, pp. 7045-7046 (1993).
Routier et al., “Salen-Anthraquinone Conjugates. Synthesis, DNA-Binding and Cleaving Properties, Effects on Topoisomerases and Ctotoxicity”,Bioorganic&Medicinal Chemistry,4(8), pp. 1185-1196 (1996).
Luengo Juan I.
Miller Stephen G.
Dustman Wayne L.
King William T.
Kinzig Charles M.
SmithKline Beecham Corporation
Weddington Kevin E.
LandOfFree
Metal complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metal complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metal complexes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2476815